Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus (Albumin-bound) in Advanced Malignant PEComa
NCT05625919Phase 2Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Nov 2022
- Primary completion
- Nov 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nab-sirolimus in malignant perivascular epithelioid cell tumor, soft tissue sarcoma (STS), sponsored by CSPC ZhongQi Pharmaceutical Technology. Status: unknown.
02
Drugs
nab-sirolimus
03
Conditions
malignant perivascular epithelioid cell tumorsoft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05625919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05625919.